Transcript NEWS YOU CAN USE 2015 11 UPD

News You Can Use…
Josh Stewart, PharmD Candidate 2016
Pete Koval, PharmD
Cone Health Family Medicine
October 2015
Drug Approval Extension
• Spiriva (tiotropium) is now FDA-
approved in asthma with Respimat
• Was previously only indicated for COPD
• Asthma dose: 2 inh once daily of 1.25mcg
(1.25mcg x 2 inhalations) = total 2.5mcg
• COPD dose: 2.5mcg X 2 inh = total 5mcg
09/16/15 boehringer-ingelheim.com
New Drug Approval
• Veltassa (patiromer) gained FDA
approval for hyperkalemia
• Not indicated for acute treatment
• Used for patients with chronic
hyperkalemia on RAAS inhibitors
10/22/2015 FDA.gov
New Drug Approval
• The FDA has approved the use of
Aristada (aripiprazole lauroxil)
extended release injection to treat
schizophrenia
• It is the 2nd once-monthly aripiprazole
injection approved by the FDA (Abilify
Maintena)
10/06/2015 FDA.gov
New Drug Approval
• Dyanavel XR (amphetamine) has been
approved by the FDA for the treatment
of ADHD in children 6 years and older
• It is an oral suspension that contains
both extended-release and immediaterelease properties
10/20/2015 prenewswire.com
Generic Drug Availability
• Paliperidone (Invega) is now available
as a generic formulation
• It is indicated for treatment of
schizophrenia in patients 12 and older
9/29/2015 PharmacyTimes.com
P&T Committee
• Ivabradine (Corlanor®) is now on
Cone Health’s formulary
• Indicated for reduction of hospitalizations in
people with worsening heart failure who meet
the following criteria:
• Stable symptomatic CHF with LVEF <35%
• In sinus rhythm with resting heart rate > 70 bpm
• On maximally tolerated beta blockers or have a
contraindication to beta blocker use
10/21/15 Cone Health P & T
P&T Committee
• Rapivab (peramivir) will NOT be added
to the Cone Health formulary
• Injectable antiviral for influenza
• Concerns: high cost, IV formulation,
not approved for pediatric use
10/21/2015
Cone Health P & T
Trial Review
• Jardiance (empagliflozin) showed CV
and mortality benefit in diabetic
patients against placebo in a recent
study
• Patients randomized to empagliflozin
10mg, 25mg, or placebo for >3 years
• Patients on empagliflozin showed a lower
rate of cardiovascular events and death
from any cause
9/17/2015 N Engl J Med